Novartis data confirms rapid response of Cosentyx® in China study
Category: #health  By Mateen Dalal  Date: 2019-03-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novartis data confirms rapid response of Cosentyx® in China study

The study proves to offer clear or almost clear skin in 8/10 patients within 16 weeks of Cosentyx® 300mg treatment.

Swiss pharmaceutical major, Novartis AG (NVS) has recently announced that its data from a Phase III study conducted on 441 Chinese patients with moderate to severe plaque psoriasis confirmed rapid response and high efficiency of Cosentyx®.

For the record, Cosentyx® is a biological and the first and only treatment that specifically prevents IL-17A, a messenger protein involved in the development of psoriatic disease, including psoriatic arthritis (PsA), psoriasis (PsO) and ankylosing spondylitis (AS).

According to sources, the data, being part of a larger ongoing 52-week Phase III study in 543 patients, showed that around 9/10 patients subjected to Cosentyx® 300mg achieved clear or near clear skin during the first 16 weeks of treatment, with rapid relief attained as early as 3 weeks.

The company said that Cosentyx® is backed by a wealth of research with 100 studies and has been proven to offer clear or nearly clear skin in 8/10 patients within 16 weeks of treatment. Nearly 100% of response rates are maintained up to 5 years.

According to a press release, Eric Hughes, Head of Global Development Unit, Immunology, Hepatology & Dermatology, and Head of China Region Development, Novartis, said that Cosentyx® continues to meet the needs of psoriasis patients, reimagining care to provide clear skin and a complete treatment.

He said that the company is excited to report its data for the first-time for the Chinese population and to see strong support from the data for Cosentyx®.

For the record, Cosentyx® has demonstarted fast and sustained long-term efficacy, besides a consistent favorable safety profile, with almost zero injection pain and site reactions. It is approved in over 80 countries, which includes the EU countries and the U.S., and is supported by 100 studies in the real world and clinical settings.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Deciphera to present data from DCC-3014 trial at CTOS annual meet
Deciphera to present data from DCC-3014 trial at CTOS annual meet
By Mateen Dalal

The ongoing clinical trial of DCC-3014 have shown preliminary anti-tumor activity.    DCC-3014 validates emerging tolerability profile with no Grade 3 or Higher TEAEs.   Encore presentation of data from the INVICTUS Pivotal Phase...

Roches risdiplam meets primary endpoint results in phase 3 trial
Roches risdiplam meets primary endpoint results in phase 3 trial
By Mateen Dalal

Spinal muscular atrophy (SMA) is a genetic neuromuscular condition, affecting approx. 1 in 6,000 babies born globally each year. Numerous healthcare companies throughout the world are putting their best foot forward to develop an effective ...

Disney+ all set for a March 2020 launch in the United Kingdom
Disney+ all set for a March 2020 launch in the United Kingdom
By Mateen Dalal

The entertainment behemoth is launching its much-awaited streaming platform.   Release of more than 300 movies is on the cards. Disney has finally asserted that new streaming service Disney+ will be rolled out soon in the U.K. Disney+ goes...